Guggenheim raises Erasca stock price target to $21 on pipeline progress

Guggenheim upgraded its price target on Erasca Inc (NASDAQ:ERAS) stock to $21 from $20 on Wednesday, retaining a Buy rating. The current stock price stands at $18.58, with targets ranging from $18 to $30. Over the past year, shares have surged more than 1,000%, showcasing growing investor confidence in the company's RAS inhibitor pipeline.

Erasca's second-quarter 2026 results and pipeline update were recently disclosed. The firm presented updated Phase 1 AURORAS-1 study data for ERAS-0015, a pan-RAS inhibitor, both as monotherapy and in combination with panitumumab. Management revealed plans to prioritize advancing ERAS-0015 development in non-small cell lung cancer and first-line pancreatic ductal adenocarcinoma towards potential pivotal study initiations in 2027.

Erasca also announced a Phase 1 clinical collaboration with Merck to assess an ERAS-0015 plus pembrolizumab combination in RAS-mutant solid tumors, to be run by Erasca. The company raised $500 million in equity in July, ending the quarter with $409 million in cash and equivalents. With a strong current ratio of 8.29, Erasca's liquid assets far exceed short-term obligations.

However, InvestingPro analysis indicates the stock may be overvalued at its current price relative to its Fair Value estimate. Guggenheim projects first clinical data from Erasca's other program, ERAS-4001, a pan-KRAS inhibitor, in solid tumors in the second half of 2026. Additionally, Erasca recently completed a public stock offering, raising approximately $632.5 million by selling 36.1 million shares at $17.50 per share.

Analysts from H.C. Wainwright and Jefferies have also raised their price targets for Erasca, citing progress in the ERAS-0015 program and strong trial data.